598 filings
Page 2 of 30
6-K
w3b11qgb
21 Sep 23
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
6:05am
6-K
905lfxuo4pk1 cj4t0j
2 Aug 23
Immutep Receives Positive Scientific Advice from European Medicines Agency
12:00am
6-K
ss9mzicw
31 Jul 23
Immutep Quarterly Activities Report & Appendix 4C
9:12pm
6-K
7yxfzscx1wf2twhmx ez
28 Jul 23
Current report (foreign)
6:31am
6-K
9f03k504x3git
27 Jun 23
Immutep Secures Third United States Patent for Eftilagimod Alpha
7:08pm
6-K
3wpoatvf
20 Jun 23
Current report (foreign)
6:45pm
6-K
zqi28rtg
5 Jun 23
Immutep Reports Final Positive Data in 2nd Line Head and Neck Squamous
8:55pm
6-K
a1iz16spn
2 Jun 23
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
6:19pm
6-K
cwcdwxdm
30 May 23
Current report (foreign)
8:18pm
6-K
ac3q21f
26 May 23
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
6:10am
6-K
mgudxrc71ndrsyse
25 May 23
Current report (foreign)
6:06am
6-K
37g6um66n4azmezlj
24 May 23
Immutep Announces Promising New Clinical Data from Triple Combination
6:54pm
6-K
pd65hsysw2gai
17 May 23
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial
6:06am
6-K
eo66xz4o ngij
16 May 23
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development
6:09am
6-K
9b3x95j3p6t6tbq3ywmu
2 May 23
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating
12:00am
6-K
6p5dxr n0qk
28 Apr 23
Immutep Quarterly Activities Report & Appendix 4C
6:10am
6-K
1kekg zkc
17 Apr 23
Immutep Announces Initiation of Investigator-Initiated Phase II Trial in Soft Tissue Sarcoma in Neoadjuvant Setting
9:09pm
6-K
i12t8qo137kppnvrt
11 Apr 23
Immutep Announces Changes to the Board
6:06am
6-K
pbu2q6
31 Mar 23
Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients
5:45pm
6-K
o9fpk4
30 Mar 23
Immutep Announces Expansion of Triple Combination Therapy
5:45pm